Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board
SAN DIEGO, CA, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis and other life-threatening disorders, today announced the appointment of H. David Humes, MD to its Scientific Advisory Board.
Dr. Humes is an internationally respected thought leader whose medical expertise is highly regarded across multiple industry segments. He has recently played an instrumental role in the oversight of preclinical and animal studies of Sigyn Therapy and is anticipated to be a valuable contributor to the further clinical advancement of Sigyn Therapy.
Sigyn Therapy is an extracorporeal blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide.
Dr. Humes is an internationally recognized nephrologist and physician scientist. He received his B.A. in mathematics/physics from University of California, Berkeley and his M.D. from University of California, San Francisco as a Regent Scholar. He completed further training at UCSF, University of Pennsylvania and Harvard. He has been appointed to the faculty at Harvard Medical School and University of Michigan. Currently, he is Professor of Internal Medicine at University of Michigan after serving as Chairman of the Department. He is considered a world-renowned scholar in the areas of nephrology, acute renal failure, cell therapy, biomaterials, device formulation, tissue engineering, and extracorporeal therapy. He has published over 250 scientific articles and book chapters, edited 6 medical textbooks, and has over 70 issued or applied patents. He has served on numerous editorial boards of scientific and medical journals. He has founded 4 spinout biomedical companies raising over $100 million of private equity. His research has been funded with over $40 million of grants from federal agencies and foundations. His accomplishments have been recognized as an Established Investigator of the American Heart Association, President’s Award of National Kidney Foundation, A.N. Richards Distinguished Achievement Award in Nephrology, Special Recognition Award from Association of Professors of Medicine, and Kolff Award in Regenerative Medicine. He is an elected member of the American Society of Clinical Investigation and the American Association of Physicians and a Fellow of American Association for the Advancement of Science and American Institute for Biological and Medical Engineering.
About Sigyn Therapeutics™
Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide. Sigyn Therapy™ is a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream.
Beyond establishing a novel strategy to combat sepsis, candidate treatment indications for Sigyn Therapy include, but are not limited to; emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases.
To learn more, visit www.SigynTherapeutics.com
Cautionary Note Regarding Forward-Looking Statements
This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Sigyn Therapeutics, Inc.
Russo Partners, LLC
Released March 15, 2022